RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. on September 20, 2023. The filing serves as a Regulation FD disclosure regarding the release of efficacy and safety results from the Company's Phase 3 RELIANCE – OLS (Long-term, Open-label) registrational study for REL-1017, a treatment for major depressive disorder.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial updates and regulatory disclosures rather than financial performance.
Material Changes
The primary material event reported is the issuance of a press release on September 20, 2023, detailing results from the Phase 3 RELIANCE – OLS study. No financial material changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical study results. The filing explicitly states that the information furnished in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings. No specific forward-looking guidance, risk factors, or contingencies are detailed within the body of this 8-K.
Key Facts for Investor Verification
- Verify the specific efficacy and safety data points in the attached press release (Exhibit 99.1) regarding the REL-1017 Phase 3 study.
- Confirm the regulatory implications of the RELIANCE – OLS study results for the approval of REL-1017 for major depressive disorder.
- Note that the clinical data in this filing is "furnished" and not "filed," meaning it carries different liability standards under the Exchange Act.
- Review the Company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial statements.